首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   389484篇
  免费   27855篇
  国内免费   9708篇
耳鼻咽喉   4253篇
儿科学   9916篇
妇产科学   6974篇
基础医学   29542篇
口腔科学   8508篇
临床医学   43200篇
内科学   45920篇
皮肤病学   5128篇
神经病学   20107篇
特种医学   9498篇
外国民族医学   35篇
外科学   38689篇
综合类   62511篇
现状与发展   21篇
一般理论   51篇
预防医学   38671篇
眼科学   5556篇
药学   35769篇
  586篇
中国医学   47462篇
肿瘤学   14650篇
  2024年   1511篇
  2023年   6723篇
  2022年   11848篇
  2021年   16036篇
  2020年   15178篇
  2019年   20296篇
  2018年   17565篇
  2017年   14957篇
  2016年   12457篇
  2015年   11605篇
  2014年   24461篇
  2013年   25141篇
  2012年   22258篇
  2011年   23801篇
  2010年   19212篇
  2009年   17079篇
  2008年   16243篇
  2007年   16777篇
  2006年   14461篇
  2005年   12507篇
  2004年   10158篇
  2003年   8902篇
  2002年   6943篇
  2001年   6277篇
  2000年   5150篇
  1999年   4430篇
  1998年   3573篇
  1997年   3406篇
  1996年   2889篇
  1995年   2765篇
  1994年   2646篇
  1993年   2089篇
  1992年   2096篇
  1991年   1837篇
  1990年   1616篇
  1989年   1425篇
  1988年   1350篇
  1985年   3824篇
  1984年   4832篇
  1983年   3356篇
  1982年   3821篇
  1981年   3572篇
  1980年   3179篇
  1979年   2914篇
  1978年   2540篇
  1977年   1916篇
  1976年   2156篇
  1975年   1635篇
  1974年   1434篇
  1973年   1278篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
重组人红细胞生成素治疗肾性贫血的临床分析   总被引:1,自引:0,他引:1  
目的 观察重组人红细胞生成素 (RhEPO)对肾性贫血的治疗作用。方法 根据使用EPO剂量的不同将 39例慢性肾衰竭并血液透析病人分成 4组 ,观察治疗后 2、4、12个月时与治疗前 (0月 )相比红细胞数 (RBC)、红细胞比积 (Hct)及血红蛋白含量 (Hb)的变化。结果  2 4例使用EPO10 0 - 15 0IU/ (kg·w) (6 0 0 0IU/w - 90 0 0IU/w) ,治疗后RBC、Hct、Hb较治疗前有显著升高 (P≤ 0 .0 0 1) ;5例使用EPO5 0IU/ (kg·w) (30 0 0IU/w) +间断输血患者 ,其RBC、Hct、Hb升高不显著 ;10例不用EPO而单纯输血患者 ,其RBC、Hct、Hb无明显变化 (P >0 .0 5 )。结论 EPO能较好地纠正肾性贫血 ;单纯输血不能治疗肾性贫血  相似文献   
82.
目的:探讨铲状电极经尿道前列腺电汽化切割术中的手术经验及疗效。方法:总结了120例经尿道前列腺电汽化切割手术的治疗资料。结果:术后随访1月~2年,120倒手术患者118例治愈,2例于术后出现急性肾衰,经保守对症治疗痊愈,2例出现压力性尿失禁,经对症治疗好转。结论:铲状电极行前列腺组织的汽化切割,优于滚轮汽化电极或电极弧,术中术后出血少,术中术野清晰,安全可靠。  相似文献   
83.
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk.  相似文献   
84.
Abstract Pericardial tamponade remains a diagnostic challenge to the clinician especially when the patient is well compensated hemodynamically. We report an unusual case who sought medical help 1 month after having been stabbed in his chest. An investigation revealed a perforation of the myocardium and a pericardial tamponade. The patient survived thanks to a large organized clot that plugged the perforation. The patient was exposed to increased risk due to delayed onset, recognition, and therapy of the tamponade. Most reports on this subject deal with acute pericardial tamponade. Only few cases of delayed pericardial tamponade have been reported. A review of the relevant literature and the therapeutic approaches are discussed.  相似文献   
85.
马瑛  靳学婷 《中国新药杂志》2007,19(11):991-994
目的:运用药物经济学的方法对在我院应用的6种中药注射液进行成本-效果分析。方法:271例急性脑梗死患者依据药物治疗方案不同分为6组,即血塞通组、舒血宁组、苦碟子组、疏血通组、川芎嗪组、丹红组,分别观察疗效,并运用药物经济学的方法进行成本-效果分析。结果:疏血通组的成本为3 419.90元,总有效率最高(91.84%),6组间增量成本-效果最低。因此疏血通组是较为合理、经济的方案。  相似文献   
86.
87.
本文作者比较了不同时期的纸质病案的使用率,讨论了旧病案的缺点,如难于保存,占用空间及实用价值不大.作者提出了改进保存病案的办法.  相似文献   
88.
目的 探讨提高上尿路结石碎石成功率的微创治疗方法。方法 采用经皮肾穿微造瘘输尿管镜气压弹道碎石,术中放置双J管,术后配合体外冲击波碎石术(ESWL)治疗上尿路结石48例。结果 结石总排净率为89.1%,结石最小排净率79.2%,无严重并发症发生。结论 该方法结石排净率高,创伤较小,手术并发症少,是上尿路结石较为理想的微创治疗方法。  相似文献   
89.
After removal of intraductal stones, a 10‐Fr or 7‐Fr pancreatic stent was placed in 16 patients with upstream ductal dilation proximal to a stricture of the main pancreatic duct. Stents were removed after a mean duration of 52.5 days. Nine patients underwent repeated stenting. About one year after removal of the initial stent, when the remaining upstream ductal dilation was found on follow‐up pancreatograms, the next stent was replaced. Repeated stenting improved outflow of pancreatic juice more effectively than one‐time stenting. Correlation between long‐term pain relief without recurrence of intraductal stones and reduction of duct diameter was also shown. Stent occlusion was observed in 14 of 30 stents. Stent occlusion was frequently associated with recurrence of pancreatitis and intraductal stones, and was also associated with morphologic changes in the pancreatic ductal system. Although there were no significant differences between stent patency of the initial stents and that of the next stents, stent patency of 10‐Fr stents was superior to that of 7‐Fr stents. 10‐Fr stents should be removed within 8 weeks and 7‐Fr stents should be removed within 4 weeks for the prevention of stent occlusion. Repeated stenting with short‐term stenting is therefore considered a safe and effective protocol of endoscopic pancreatic stenting.  相似文献   
90.
The naevus of Ota (naevus fusculocoeruleus ophthalmomaxillaris) was first described by the Japanese dermatologist M. T. Ota in 1939. It has a reported incidence of 0.2% to 1% in the Japanese population. It usually occurs in the skin innervated by the first or second branch of the trigeminal nerve. The naevus comprises dermal melanocytes and is congenital or acquired during adolescence. Commonly associated lesions include scleral melanocytosis and other ocular manifestations as well as lesions of the tympanic membrane, oral and intranasal mucosa and leptomeninges. Diseases associated with Ota's naevus in rare cases are open-angle glaucomas and melanoma. The naevus of Ota in Europeans is a rare manifestation. We report the very rare case of a bilateral naevus of Ota associated with enoral melanocytosis in a white European person.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号